LarvolClinCancer Trial Results
Trials Conferences Kaplan-Meier Plot Forest Plot Influencers
menu
Back

ESMO-GC 2021 - ESMO GYNAECOLOGICAL CANCERS 2021 (VIRTUAL MEETING)

Jun 25 - Jun 26, 2021 | LuganoSwitzerland

LARVOL is not affiliated with ESMO GYNAECOLOGICAL CANCERS 2021 (VIRTUAL MEETING) and all trademarks, logos, and brand names are property of their respective owners

Condition
Stage
Treatment
Setting
Biomarker
Trial Name/ID

Showing 4 titles linked to Trials

[VIRTUAL] Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

  • IMagyn050

[VIRTUAL] Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation

  • SOLO-2

[VIRTUAL] Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase 3 study

  • ARIEL4

[VIRTUAL] Long term safety and secondary efficacy end points in the ENGOT-OV16/NOVA phase 3 trial on Niraparib in recurrent ovarian cancer

  • NOVA

Copyright © LARVOL 2023. All rights reserved.

  • Privacy Policy
  • Terms of Service
clear

Trials

Conferences

Kaplan-Meier Plot

Forest Plot

Influencers

Feedback

Privacy Policy Terms of Service